Since 2017, the FDA has approved several clinical treatment regimens for AML, including small molecule inhibitors, such as FLT3 inhibitors, antibody-drug conjugates, and cytotoxic agents. This evidence concerns the gene FLT3 and acute myeloid leukemia.